|
rs1012657750
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Patients with high Hcy and MTHFR 667CC, as well as those with low Hcy and 667CT+TT, showed lower odds of uncontrolled SBP (MTHFR 667CC+ high Hcy: OR: 0.338, 95% CI: 0.115-0.996, Pcombined = 0.049; MTHFR 667CT/TT+ low Hcy: OR: 0.421, 95% CI: 0.193-0.921, Pcombined = 0.030) compared to patients with low Hcy and MTHFR 667CC.<b>Conclusions</b>: Serum Hcy status and Hcy metabolism gene polymorphisms (MTHFR C667T and MTRR A66G) may have synergistic effects on the prevalence of HTN and dyslipidemia.
|
30786773 |
2020 |
|
rs11961407
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Patients with high Hcy and MTHFR 667CC, as well as those with low Hcy and 667CT+TT, showed lower odds of uncontrolled SBP (MTHFR 667CC+ high Hcy: OR: 0.338, 95% CI: 0.115-0.996, Pcombined = 0.049; MTHFR 667CT/TT+ low Hcy: OR: 0.421, 95% CI: 0.193-0.921, Pcombined = 0.030) compared to patients with low Hcy and MTHFR 667CC.<b>Conclusions</b>: Serum Hcy status and Hcy metabolism gene polymorphisms (MTHFR C667T and MTRR A66G) may have synergistic effects on the prevalence of HTN and dyslipidemia.
|
30786773 |
2020 |
|
rs1211098985
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Patients with high Hcy and MTHFR 667CC, as well as those with low Hcy and 667CT+TT, showed lower odds of uncontrolled SBP (MTHFR 667CC+ high Hcy: OR: 0.338, 95% CI: 0.115-0.996, Pcombined = 0.049; MTHFR 667CT/TT+ low Hcy: OR: 0.421, 95% CI: 0.193-0.921, Pcombined = 0.030) compared to patients with low Hcy and MTHFR 667CC.<b>Conclusions</b>: Serum Hcy status and Hcy metabolism gene polymorphisms (MTHFR C667T and MTRR A66G) may have synergistic effects on the prevalence of HTN and dyslipidemia.
|
30786773 |
2020 |
|
rs1249051329
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Patients with high Hcy and MTHFR 667CC, as well as those with low Hcy and 667CT+TT, showed lower odds of uncontrolled SBP (MTHFR 667CC+ high Hcy: OR: 0.338, 95% CI: 0.115-0.996, Pcombined = 0.049; MTHFR 667CT/TT+ low Hcy: OR: 0.421, 95% CI: 0.193-0.921, Pcombined = 0.030) compared to patients with low Hcy and MTHFR 667CC.<b>Conclusions</b>: Serum Hcy status and Hcy metabolism gene polymorphisms (MTHFR C667T and MTRR A66G) may have synergistic effects on the prevalence of HTN and dyslipidemia.
|
30786773 |
2020 |
|
rs36217263
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The deletion of at least one copy of allele A of rs36217263 near Klotho showed statistically significant association with poor response to beta-blockers (dominant; odds ratio (OR) = 3.89; P = 0.017), adjusted for diabetes and dyslipidemia.
|
31350855 |
2020 |
|
rs762304200
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Patients with high Hcy and MTHFR 667CC, as well as those with low Hcy and 667CT+TT, showed lower odds of uncontrolled SBP (MTHFR 667CC+ high Hcy: OR: 0.338, 95% CI: 0.115-0.996, Pcombined = 0.049; MTHFR 667CT/TT+ low Hcy: OR: 0.421, 95% CI: 0.193-0.921, Pcombined = 0.030) compared to patients with low Hcy and MTHFR 667CC.<b>Conclusions</b>: Serum Hcy status and Hcy metabolism gene polymorphisms (MTHFR C667T and MTRR A66G) may have synergistic effects on the prevalence of HTN and dyslipidemia.
|
30786773 |
2020 |
|
rs771038258
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Patients with high Hcy and MTHFR 667CC, as well as those with low Hcy and 667CT+TT, showed lower odds of uncontrolled SBP (MTHFR 667CC+ high Hcy: OR: 0.338, 95% CI: 0.115-0.996, Pcombined = 0.049; MTHFR 667CT/TT+ low Hcy: OR: 0.421, 95% CI: 0.193-0.921, Pcombined = 0.030) compared to patients with low Hcy and MTHFR 667CC.<b>Conclusions</b>: Serum Hcy status and Hcy metabolism gene polymorphisms (MTHFR C667T and MTRR A66G) may have synergistic effects on the prevalence of HTN and dyslipidemia.
|
30786773 |
2020 |
|
rs10488698
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Six functional SNPs (<i>APOA1</i> rs5072, <i>APOC3</i> rs5128, <i>APOA4</i> rs5104, <i>APOA5</i> rs651821, <i>ZPR1</i> rs2075294 and <i>BUD13</i> rs10488698) were genotyped using polymerase chain reaction and MALDI-TOF-MS. Logistic regression analysis was performed to explore the relationship of <i>APOA1/C3/A4/A5-ZPR1-BUD13</i> gene cluster gene polymorphisms with dyslipidemia.
|
30631647 |
2019 |
|
rs1049353
|
|
|
0.010 |
GeneticVariation |
BEFREE |
G1359A Polymorphism of the Cannabinoid Receptor 1 Is Not Associated with Overweight and Dyslipidemia in Young Northeastern Mexicans.
|
31723535 |
2019 |
|
rs1121923
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Moreover, the findings indicate the potential for including rs1121923 and rs258 in diagnostic panels for use as an estimator of "risk" scores for dyslipidemia.
|
30944368 |
2019 |
|
rs1289389
|
|
|
0.010 |
GeneticVariation |
BEFREE |
SLC15A1 rs2297322 and rs1289389 polymorphisms were associated with alterations in the risk of dyslipidaemia in a Chinese Han population.
|
31454435 |
2019 |
|
rs1801725
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CASR polymorphisms (rs7652589, rs1801725) are associated with dyslipidemia in HD patients.
|
31775661 |
2019 |
|
rs2075294
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Six functional SNPs (<i>APOA1</i> rs5072, <i>APOC3</i> rs5128, <i>APOA4</i> rs5104, <i>APOA5</i> rs651821, <i>ZPR1</i> rs2075294 and <i>BUD13</i> rs10488698) were genotyped using polymerase chain reaction and MALDI-TOF-MS. Logistic regression analysis was performed to explore the relationship of <i>APOA1/C3/A4/A5-ZPR1-BUD13</i> gene cluster gene polymorphisms with dyslipidemia.
|
30631647 |
2019 |
|
rs2278426
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our results suggest that the rs2278426 (C/T) variant is associated with increased risk of T2DM and may cause dyslipidemia due to its effect on decreasing HDL-C levels.
|
30191588 |
2019 |
|
rs2297322
|
|
|
0.010 |
GeneticVariation |
BEFREE |
SLC15A1 rs2297322 and rs1289389 polymorphisms were associated with alterations in the risk of dyslipidaemia in a Chinese Han population.
|
31454435 |
2019 |
|
rs2472386
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Polymorphisms of rs4149339, rs4743763 and rs2472386 in <i>ABCA1</i> and three lifestyle factors (physical activity, fried food intake, and dessert intake) were associated with CAD in people with dyslipidemia in southern China.
|
30836684 |
2019 |
|
rs258
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Moreover, the findings indicate the potential for including rs1121923 and rs258 in diagnostic panels for use as an estimator of "risk" scores for dyslipidemia.
|
30944368 |
2019 |
|
rs4149339
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Polymorphisms of rs4149339, rs4743763 and rs2472386 in <i>ABCA1</i> and three lifestyle factors (physical activity, fried food intake, and dessert intake) were associated with CAD in people with dyslipidemia in southern China.
|
30836684 |
2019 |
|
rs4743763
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Polymorphisms of rs4149339, rs4743763 and rs2472386 in <i>ABCA1</i> and three lifestyle factors (physical activity, fried food intake, and dessert intake) were associated with CAD in people with dyslipidemia in southern China.
|
30836684 |
2019 |
|
rs5072
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Furthermore, the association of <i>APOA1</i> rs5072 in this gene cluster with dyslipidemia differed between genders; thus, additional studies are needed to confirm this conclusion, and the mechanisms underlying these results warrant further exploration.
|
30631647 |
2019 |
|
rs5104
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Six functional SNPs (<i>APOA1</i> rs5072, <i>APOC3</i> rs5128, <i>APOA4</i> rs5104, <i>APOA5</i> rs651821, <i>ZPR1</i> rs2075294 and <i>BUD13</i> rs10488698) were genotyped using polymerase chain reaction and MALDI-TOF-MS. Logistic regression analysis was performed to explore the relationship of <i>APOA1/C3/A4/A5-ZPR1-BUD13</i> gene cluster gene polymorphisms with dyslipidemia.
|
30631647 |
2019 |
|
rs5128
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Six functional SNPs (<i>APOA1</i> rs5072, <i>APOC3</i> rs5128, <i>APOA4</i> rs5104, <i>APOA5</i> rs651821, <i>ZPR1</i> rs2075294 and <i>BUD13</i> rs10488698) were genotyped using polymerase chain reaction and MALDI-TOF-MS. Logistic regression analysis was performed to explore the relationship of <i>APOA1/C3/A4/A5-ZPR1-BUD13</i> gene cluster gene polymorphisms with dyslipidemia.
|
30631647 |
2019 |
|
rs763000109
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The MnSOD Ala16Val single nucleotide polymorphism (SNP) has shown to be associated to inflammatory pathways and many metabolic disorders, such as obesity and dyslipidemia.
|
31212050 |
2019 |
|
rs7652589
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CASR polymorphisms (rs7652589, rs1801725) are associated with dyslipidemia in HD patients.
|
31775661 |
2019 |
|
rs78338345
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our evolutionary analyses suggest that derived alleles of rs78338345 of GGA3, rs7656604 at 4q13.3, rs34902660 of SLC17A3, and six SNPs closely located at 12q24.1 associated with type 2 diabetes mellitus, obesity, dyslipidemia, and three complex disorders (hypertension, hyperuricemia, and dyslipidemia), respectively, rapidly expanded after the human dispersion from Africa (Out-of-Africa).
|
31402603 |
2019 |